Lambda

Igλ light chain is one of the light chain subtypes of immunoglobulin. It forms the antigen binding site together with the heavy chain to specifically recognize and bind antigens. As a characteristic product of B cells and plasma cells, Igλ is mainly used in combination with Igκ in clinical practice to assist in the diagnosis of benign and malignant lesions of the lymphoid and hematopoietic system, including B-cell lymphoma, MALT lymphoma, multiple myeloma, light chain deposition disease, and primary amyloidosis. In addition, some epithelial tumors such as liver cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, and breast cancer may undergo gene rearrangement and abnormally secrete Ig, which may mediate immune escape by interfering with immune response, or utilize growth factor activity to promote tumor development. In addition, some research suggested that Igλ in cervical cancer may inhibit apoptosis by blocking the P53 pathway, while enhancing chromatin relaxation related gene activation and promote proliferation related gene expression by interaction with histone H1 subtype.